医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GC Biopharma Reports Q2 2022 Results

2022年08月02日 AM01:00
このエントリーをはてなブックマークに追加


 

YONGIN, South Korea

GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022.

Second-Quarter Reported Results

Key Figures

Q2 2022

Growth(1)

Total revenues

KRW 423.2 billion

9.2%

Operating Income

KRW 13.1 billion

18.0%

Net Income

KRW 10.9 billion

45.3%

(1) Results and percentages compare to Q2 2021

Financial Highlights

  • Delivered total revenue growth of 9.2% KRW 423.2 billion (Q2 2021: 387.6 billion), and operating profit increased 18.0% to KRW 13.1 billion (Q2 2021: 11.1 billion) in the second quarter
  • Unconsolidated revenues growth of +9.7% driven by strong performance of Vx and Protein businesses international sales
  • Maintain double-digit growth in consolidated subsidiaries, including GC Cell(+90.9% YoY) and GC WB(+15.0% YoY), except GC MS(-57.9% YoY)
  • International Protein and Vx sales growth of 62.4% and 11.2% respectively. In particular, Flu Vx sales recorded the highest performance with improved performance notably in Southern Hemisphere
  • Continue to expect strong growth from local/international business across all segments in second half of the year
  • Gross profit margin growth of 3.4%p due to product-mix optimization

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century.

This press release may contain forward-looking statements, which express the current beliefs and expectations of GC Biopharma’s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005312/en/

CONTACT

Investor/Media Contact

Yelin Jun

yelin@gccorp.com

Sohee Kim

shkim20@gccorp.com

Hansaem Kim

hs.kim@gccorp.com

Haeun Yoon

cutty980117@gccorp.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer
  • エクセンシアの2022年第2四半期および上半期ビジネスアップデート
  • Exscientia通报2022年二季度和上半年业务进展
  • European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer
  • Aurion Biotech Nominated for Prix Galien Startup Award